In-vivo potential of Musa paradisiaca Linn. (Stmn.) in streptozotocin-induced diabetic rats

Abstract

Objective: Musa paradisiaca belonging to family Musaceae is a well-known herb having many pharmacological properties including antidiabetic activity. In ancient text, Basavaraju was reported the stamen of this plant as antidiabetic agent in a dietary recipe. The main aim of this study was to explore the in-vivo antidiabetic property of its stamen. Materials and Methods: Aqueous extract of M. paradisiaca stamen (AqMP, 100, 200, and 400 mg/kg, p.o.) was evaluated for hypoglycemic effect in normoglycemic rats and consequences on oral glucose tolerance test (OGTT) by measuring the tail blood glucose concentrations. Further, blood glucose level was measured after 7th, 14th, and 21th days in streptozotocin-nicotinamide (STZ 65 mg/kg, i.p. and NDA 110 mg/kg, i.p.) induced-diabetic rats treated with AqMP and reference drug glibenclamide (5 mg/kg, b.w. p.o.). Results: The result with normoglycemic rats shows that the AqMP (400 mg/kg, p.o.) did not have any hypoglycemic effect, and it effectively control the blood glucose level in OGTT within 30-60 min after glucose (2 g/kg) administration without causing any hypoglycemic effect. Moreover, the drug (400 mg/kg, p.o.) was also found to be effective in controlling the blood sugar level in STZ-NDA induce diabetic rat as compare to glibenclamide. Conclusion: The study shows that the drug exhibit significant in-vivo antidiabetic potential as well as support its traditional use in diabetes.